TNFRSF4 and neoplasm: Importantly, 6 out of 10 (60%) mice treated with PL1-OX40 + anti-OX40 Ab exhibited a complete response (Fig. 3d) and were resistant to A20 tumor rechallenge (Fig. 3e).